A New Alternative in The Treatment of Hyperprolactinemia: Cabergoline
PDF
Cite
Share
Request
Original Article
P: 44-46
March 1998

A New Alternative in The Treatment of Hyperprolactinemia: Cabergoline

İstanbul Med J 1998;2(1):44-46
1. SSK İstanbul Eğitim Hastanesi, 5. Dahiliye Kliniği
2. İstanbul Eğitim Ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İstanbul
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Hyperprolacinoma is a frequent cause of amenorrhea, infertility, and galactorrhea in women and decreased libido and impotence in men. Idiopathic hyperprolactinemia can be treated with drugs, and prolactinomas can be treated by drug therapy, surgery, or radiation therapy. Bromocriptine has been standard drug for hyperprolactinemia. However 5 to 10 percent ofpatients cannot tolerate the drug because of side effects. Cabergoline is an important advance in the treatment of hyperprolactinemia, because is need be taken only twice weekly and is better tolerated and at least as effective as bromocriptine. A female patient with hyperpolactinemia due to protaetinoma who was unresponsive to standard bromocriptine therapy, and could not tolerate higher doses of the drug, treated with cabergoline has been presented in this case report.